The Sterling Institutional Review Board (IRB) featured PEGUS Research’s innovative and versatile marketing strategies in their latest Whitepaper article titled “PPC and Social Media Patient…
John EvansApril 12, 2022
Latest News
On 17 June 2021, the US Food and Drug Administration (FDA) announced approval of a new nasal antihistamine (Astepro Allergy and Children’s Astepro Allergy) for…
John EvansJune 21, 2021
Clark Richardson, PEGUS President & CEO, participated in a 09 June 2021 FDA public workshop titled, “The Nonprescription Drug Facts Label in a Changing Consumer…
John EvansJune 14, 2021
Innovating at Unprecedented Pace COVID-19 prompted dramatic changes in the way we conduct research. In the months since the pandemic began, we have completed literally…
John EvansFebruary 8, 2021
We are pleased to announce Brandon Henrie has been promoted to Vice President – Finance and Strategy. In this new role, Brandon focuses on company…
John EvansFebruary 8, 2021
On 28 Feb. 2020, the US Food and Drug Administration (FDA) approved a novel fixed-dose combination oral pain reliever (Advil Dual Action with Acetaminophen) for…
John EvansMarch 5, 2020
An analysis of the use of time sampling strategies (subject reports of medication dosing behavior in the period preceding a study contact) compared to daily…
John EvansSeptember 15, 2019
Learn more about PEGUS
Our Pharmaceutical Research Services
Learn More
Join our Pharmacy Network.
Are you a registered pharmacist interested in joining our network?
Learn More
